Quarterly Institutional Activity in CYCC

Shares Bought
Shares Sold
View Transactions

Top Institutions Holding CYCC

View all

Latest Institutional Activity in CYCC

Top Purchases

Q3 2023
Kpp Advisory Services LLC Shares Held: 30.2K ($34.4K)
Q3 2023
Geode Capital Management, LLC Shares Held: 86.4K ($98.5K)
Q3 2023
Citadel Advisors LLC Shares Held: 30.7K ($35K)
Q3 2023
Renaissance Technologies LLC Shares Held: 186K ($211K)
Q3 2023
Mc Ilrath & Eck, LLC Shares Held: 12.5K ($14.2K)

Top Sells

Q3 2023
Schonfeld Strategic Advisors LLC Shares Held: 28.4K ($32.4K)
Q3 2023
Advisor Group Holdings, Inc. Shares Held: 9.15K ($10.4K)
Q3 2023
Two Sigma Investments, LP Shares Held: 16.4K ($18.7K)
Q3 2023
Tower Research Capital LLC (Trc) Shares Held: 3.59K ($4.09K)
Q2 2023
Millennium Management LLC Shares Held: 51.1K ($58.3K)

About CYCC

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.


Insider Transactions at CYCC

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
20.5K Shares
From 3 Insiders
Open market or private purchase 7.96K shares
Grant, award, or other acquisition 12.5K shares
Sell / Disposition
0 Shares
From 0 Insiders

Track Institutional and Insider Activities on CYCC

Follow Cyclacel Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CYCC shares.

Notify only if

Insider Trading

Get notified when an Cyclacel Pharmaceuticals, Inc. insider buys or sells CYCC shares.

Notify only if

News

Receive news related to Cyclacel Pharmaceuticals, Inc.

Track Activities on CYCC